España
Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
12.587 / 17.026
#100690

Re: Farmas USA

Top 100
mugiwara

HZNP

Ahora que tengo un rato le he echado un vistazo. Salvo que anuncien el lanzamiento de RAVICTI en Europa próximamente nos vamos al día 8 de mayo, día de ER, y a comernos los resultados. Lo malo: que el 1r trimestre es siempre el más flojo en ventas con diferencia. Lo bueno: que es de sobras conocido, por poco que se supere lo estimado debería "celebrarse". Se preveé una contribución al EBITDA anual muy pobre en este Q1. Dejo cuadro adjunto con esos datos: 

#100691

Re: Farmas USA

SGYP

EL CEO no se ha ido,  querrás decir el CFO, que no es para nada el investigador principal. El CEO sigue siendo el mismo (Gary Jacob), que además tiene incentivos por contrato para vender la empresa si lo hace por encima de $9.

Ya han puesto nuevo sustituto al CFO que se ha retrirado por edad. No veo mayor transcendencia.

Edito: Te has liado porque el nuevo CFO tb se llama Gary??

#100692

Re: Farmas USA

CNAT Buena info del congreso de hígado:

Conatus Posters at EASL Meeting Address MELD Score Dynamics and Outcomes in Decompensated Liver Cirrhosis Patients, Including NASH Patients, Awaiting Liver Transplantation

|GlobeNewswire|About:  CNAT

AMSTERDAM, the Netherlands, April 21, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that two posters co-authored by Conatus employees are being presented today at The International Liver Congress™ 2017, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Amsterdam, The Netherlands, April 19-23, 2017. The posters are the result of a collaborative data analysis study with senior author W. Ray Kim, M.D., Professor of Medicine, and lead author Ajitha Mannalithara, Ph.D., Engineering Research Associate, both of the Division of Gastroenterology and Hepatology at Stanford University Medical Center.

Poster #FRI-485 entitled, “Model for end stage liver disease [MELD] score dynamics in NASH [nonalcoholic steatohepatitis] patients awaiting liver transplantation and waitlist outcomes,” and poster #FRI-486 entitled “Model for end stage liver disease score dynamics in patients awaiting liver transplantation and waitlist outcomes,” will be displayed today, Friday, April 21, from 8:00 a.m. to 6:00 p.m. CET. The full posters are available in the Liver Disease Resources tab in the Data section of the Conatus website at  www.conatuspharma.com.

Summary of MELD Score Dynamics Evaluations
Analyses presented in both posters were based on data extracted from the Organ Procurement and Transplantation Network, for adults on the liver transplant waiting list on or after January 1, 2010. For the -486 poster, patient outcomes were assessed by the primary cause of cirrhosis (hepatitis C virus, NASH, alcoholic liver disease, or unknown). For the -485 poster, NASH cirrhosis patients were analyzed by baseline MELD score (<15, 15-20, or >20). The different groups were then analyzed for the ability of MELD score changes over a 12-week period to predict transplant-free survival over two years.

Regardless of etiology and regardless of baseline MELD score, patients whose MELD scores decreased by 2 points or more had a lower incidence of death or liver transplantation. Patients whose MELD scores increased had progressively higher incidences of death or liver transplantation which correlated with the degree of MELD score increase.

“One of the challenges to developing drugs in decompensated cirrhosis patients in general, and specifically in patients with NASH cirrhosis, is to identify an endpoint that predicts long-term patient outcomes and is supported by clinical data,” said David T. Hagerty, M.D., Executive Vice President of Clinical Development of Conatus, “so we were eager to work with Drs. Kim and Mannalithara in evaluating whether MELD score progression or improvement could predict long-term patient outcomes. Dr. Kim is an internationally recognized expert on the MELD score and the knowledge provided by these efforts has helped us to design the planned ENCORE-LF clinical trial in decompensated NASH cirrhosis patients.”

 

#100693

Re: Farmas USA

TGTX

Nuevos datos en breve, os recuerdo.

TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology

|GlobeNewswire|About:  TGTX

GlobeNewswire

NEW YORK, April 20, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been selected for presentation at the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held from June 2 - 6, 2017, at McCormick Place in Chicago, Illinois. Details of the data presentations are outlined below.

Oral Presentation:

  • Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study 
    • Abstract Number: 7504
    • Presentation Date & Time: Saturday, June 3, 2017 3:00 PM – 6:00 PM CT
    • Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
    • Presenter: Jeffrey P. Sharman, MD

Poster Discussion Presentation:

  • Title: Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL 
    • Abstract Number: 7511
    • Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT (Poster Viewing); 1:15 PM-2:30 PM CT (Poster Discussion)
    • Session Title: Poster Discussion Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
    • Presenter: Loretta Nastoupil, MD

Trials in Progress Poster Presentation:

  • Title: KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy 
    • Abstract Number: TPS7569
    • Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT
    • Session Title: Poster Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
    • Presenter: Colleen Dorsey, BSN, RN

The above abstracts will be released publicly on May 17, 2017 through the ASCO meeting website at  www.asco.org. Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at  www.tgtherapeutics.com.

#100694

Re: Farmas USA

Buenas.

 

¿Alguien conoce Neurotrope? Tienen una fase 2b en AD con resultados inminentes. Tengo un puñado de cromos a 19.54 $,

S2.

 

NTRP

#100695

Re: Farmas USA

http://www.businesswire.com/news/home/20170420006678/en/Rasna-Therapeutics-Names-Dr.-Kunwar-Shailubhai-CEO

Se ha ido el CSO y cofundador:

Dr. Shailubhai, who was formally appointed on April 14th, was a co-founder and served as the Chief Scientific Officer and prior Senior Vice President, Drug Discovery, of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) from 2004, where he led the development of Trulance™ from inception to FDA approval, having co-invented and pioneered Synergy’s platform technology surrounding the therapeutic applications of guanylate cyclase C agonists for functional GI disorders, inflammatory bowel disease, GI cancer, cholesterol lowering, asthma and other lung diseases.

 

SGYP